Character Strengths are Prominent as Mate Preferences of Turkish Students

This study addressed the traits and characteristics that Turkish students deem most important in a long-term romantic partner. We collected quantitative and qualitative data on characteristics desired in romantic partners from students attending Bahçeşehir Üniversitesi in Istanbul, Turkey. Like our previous cross-cultural studies conducted in Japan, Russia and the United States, results supported dependability and love as the most important traits. Overall, positive internal attributes were rated as highly important and we recommend the traits associated with the positive psychology movement be more fully considered in future studies on mate preferences

Retention and Resilience of Nursing Home Staff During the COVID-19 Pandemic: Voices from the Frontline

To the Editor: The nursing home (NH) industry has experienced a 13% drop in employment over the course of the pandemic - worse than any other health care sector - and NHs across the country continue to face dire staffing shortages with increased reliance on agency staff. Despite challenging working conditions and public blame, many NH staff have continued in their roles. This study sought to elucidate contributors to staff retention and resilience through interviews with frontline NH staff who worked 2 or more years during the pandemic

Burden of hereditary transthyretin amyloidosis on quality of life

INTRODUCTION: Hereditary transthyretin (hATTR) amyloidosis is a progressive, degenerative disease, with peripheral neuropathy, cardiomyopathy, and other clinical manifestations. In this study we examine the impact of hATTR amyloidosis on quality of life (QOL). METHODS: Neuropathy-specific QOL, measured with the Norfolk QOL-Diabetic Neuropathy questionnaire, was compared between patients with hATTR amyloidosis and patients with type 2 diabetes, whereas generic QOL, measured with the 36-item Short Form Health Survey version 2 (SF-36v2), was compared between patients with hATTR amyloidosis, the general population, and patients with chronic diseases. RESULTS: Neuropathy-specific QOL for patients with hATTR amyloidosis was nearly equivalent to that of patients with type 2 diabetes with diabetic neuropathy accompanied by a history of ulceration, gangrene, or amputation. Generic QOL was worse than that seen in the general population, with physical functioning worse than that for patients with multiple sclerosis and congestive heart failure. DISCUSSION: Patients with hATTR amyloidosis show significant burden on QOL, particularly in physical functioning. Muscle Nerve 60: 169-175, 201

Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration

Acknowledgements We are indebted to Jim Humphries, JennyCorrigan, LizDarley, Elizabeth Joynson, Natalie Walters, Sara Wells and the whole necropsy, histology, genotyping and MLC ward 6 teams at MRC Harwell for excellent technical assistance. We thank the staff of the WTSI Illumina Bespoke Team for the RNA-seq data, the Sanger Mouse Genetics Project for the initial mouse characterization and Dr David Adams for critical reading of the manuscript. We also thank KOMP for the mouse embryonic stem cells carrying the knockout first promoter-less allele (tm1a(KOMP)Wtsi) within Zfp016. Conflict of Interest statement. None declared. Funding This work was funded by the UK Medical Research Council (MRC) to A.A.-A. and a Motor Neurone Disease Association (MNDA) project grant to A.A.-A. and EMCF. D.L.H.B. is a Wellcome Trust Senior Clinical Scientist Fellow and P.F. is a MRC/MNDA Lady Edith Wolfson Clinician Scientist Fellow. Funding to pay the Open Access publication charges for this article was provided by the MRC grant number: MC_UP_A390_1106.Peer reviewedPublisher PD

Precision Analysis of Evolved Stars

Evolved stars dominate galactic spectra, enrich the galactic medium, expand to change their planetary systems, eject winds of a complex nature, produce spectacular nebulae and illuminate them, and transfer material between binary companions. While doing this, they fill the HR diagram with diagnostic loops that write the story of late stellar evolution. Evolved stars sometimes release unfathomable amounts of energy in neutrinos, light, kinetic flow, and gravitational waves. During these late-life times, stars evolve complexly, with expansion, convection, mixing, pulsation, mass loss. Some processes have virtually no spatial symmetries, and are poorly addressed with low-resolution measurements and analysis. Even a "simple" question as how to model mass loss resists solution. However, new methods offer increasingly diagnostic tools. Astrometry reveals populations and groupings. Pulsations/oscillations support study of stellar interiors. Optical/radio interferometry enable 2-3d imagery of atmospheres and shells. Bright stars with rich molecular spectra and velocity fields are a ripe opportunity for imaging with high spatial and spectral resolution, giving insight into the physics and modeling of later stellar evolution

Precision Analysis of Evolved Stars

Evolved stars dominate galactic spectra, enrich the galactic medium, expand to change their planetary systems, eject winds of a complex nature, produce spectacular nebulae and illuminate them, and transfer material between binary companions. While doing this, they fill the HR diagram with diagnostic loops that write the story of late stellar evolution. Evolved stars sometimes release unfathomable amounts of energy in neutrinos, light, kinetic flow, and gravitational waves. During these late-life times, stars evolve complexly, with expansion, convection, mixing, pulsation, mass loss. Some processes have virtually no spatial symmetries, and are poorly addressed with low-resolution measurements and analysis. Even a "simple" question as how to model mass loss resists solution. However, new methods offer increasingly diagnostic tools. Astrometry reveals populations and groupings. Pulsations/oscillations support study of stellar interiors. Optical/radio interferometry enable 2-3d imagery of atmospheres and shells. Bright stars with rich molecular spectra and velocity fields are a ripe opportunity for imaging with high spatial and spectral resolution, giving insight into the physics and modeling of later stellar evolution.Comment: Decadal2020 Science White Paper; 6 pages, 12 figure

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Objective: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. Methods: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-blind, placebo-controlled study of inotersen in patients with hATTR amyloidosis with polyneuropathy. At baseline and week 66, QOL measures-the Norfolk-QOL-Diabetic Neuropathy (DN) questionnaire and SF-36v2® Health Survey (SF-36v2)-were assessed. Treatment differences in mean changes in QOL from baseline to week 66 were tested using mixed-effect models with repeated measures. Responder analyses compared the percentages of patients whose QOL meaningfully improved or worsened from baseline to week 66 in inotersen and placebo arms. Descriptive analysis of item responses examined treatment differences in specific activities and functions at week 66. Results: Statistically significant mean differences between treatment arms were observed for three of five Norfolk-QOL-DN domains and five of eight SF-36v2 domains, with better outcomes for inotersen than placebo in physical functioning, activities of daily living, neuropathic symptoms, pain, role limitations due to health problems, and social functioning. A larger percentage of patients in the inotersen arm than the placebo arm showed preservation or improvement in Norfolk-QOL-DN and SF-36v2 scores from baseline to week 66. Responses at week 66 showed more substantial problems with daily activities and functioning for patients in the placebo arm than in the inotersen arm. Conclusion: Patients with hATTR amyloidosis with polyneuropathy treated with inotersen showed preserved or improved QOL at 66 weeks compared to those who received placebo.This research was funded by Akcea Therapeutics and Ionis Pharmaceuticals, Incinfo:eu-repo/semantics/publishedVersio